Corporate Member Merck - NEW Indication

Corporate Member Merck - NEW Indication

KEYTRUDA (Pembrolizumab)
March, 2017

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members